Assessment of Cell Viability in Drug Therapy: IC50 and Other New Time-Independent Indices for Evaluating Chemotherapy Efficacy

<b>Background/Objectives</b>: Cell viability assays play a crucial role in cancer research and the development of effective treatments. Evaluating the efficacy of conventional treatments across different tumor profiles is essential for understanding patient resistance to chemotherapy and relapse. The IC50 index has been commonly used as a guide in these assays. The idea behind the IC50 index is to compare cell proliferation under treatment with respect to a control population exposed to the same treatment. The index requires normalization to a control and is time dependent. These aspects are disadvantages, as small variations yield different results. In this article, we propose a new method to analyze cell viability assays. <b>Methods</b>: This method involves calculating the effective growth rate for both control (untreated) cells and cells exposed to a range of drug doses for short times, during which exponential proliferation can be assumed. The concentration dependence of the effective growth rate gives a real estimate of the treatment on cell proliferation. A curve fit of the effective growth rate related to concentration yields the concentration corresponding to a given effective growth rate. <b>Results</b>: We use this estimation to calculate the IC50 index and introduce two new parameters (ICr0 and ICrmed) to compare treatment efficacy under different culture conditions or cell lines. <b>Conclusions</b>: In summary, this study presents a new method to analyze cell viability assays and introduces two more precise parameters, improving the comparison and evaluation of efficacy under different conditions.

Authors

Institutions

Publication Details

Journal
Pharmaceutics
Published
2025-02-13
DOI
https://doi.org/10.3390/pharmaceutics17020247
Citations
24
Primary Topic
Statistical Methods in Clinical Trials
Type
article
Field-Weighted Citation Impact
63.12

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Assessment of Cell Viability in Drug Therapy: IC50 and Other New Time-Independent Indices for Evaluating Chemotherapy Efficacy

Josefa Quiroz‐Troncoso, Nicolás Alegría‐Aravena, Carmen Ramírez‐Castillejo, Marta Sánchez‐Díez et al.
24 citations
Pharmaceutics
Statistical Methods in Clinical Trials
63.12
article

Assessment of Cell Viability in Drug Therapy: IC50 and Other New Time-Independent Indices for Evaluating Chemotherapy Efficacy

Josefa Quiroz‐Troncoso, Nicolás Alegría‐Aravena, Carmen Ramírez‐Castillejo, Marta Sánchez‐Díez, Raquel González‐Martos, Juan Manuel Pastor, Paula Romero-Jiménez, Clara E. Gavira-O’Neill, Elena Vicente-García
article en
24 citations

Abstract

<b>Background/Objectives</b>: Cell viability assays play a crucial role in cancer research and the development of effective treatments. Evaluating the efficacy of conventional treatments across different tumor profiles is essential for understanding patient resistance to chemotherapy and relapse. The IC50 index has been commonly used as a guide in these assays. The idea behind the IC50 index is to compare cell proliferation under treatment with respect to a control population exposed to the same treatment. The index requires normalization to a control and is time dependent. These aspects are disadvantages, as small variations yield different results. In this article, we propose a new method to analyze cell viability assays. <b>Methods</b>: This method involves calculating the effective growth rate for both control (untreated) cells and cells exposed to a range of drug doses for short times, during which exponential proliferation can be assumed. The concentration dependence of the effective growth rate gives a real estimate of the treatment on cell proliferation. A curve fit of the effective growth rate related to concentration yields the concentration corresponding to a given effective growth rate. <b>Results</b>: We use this estimation to calculate the IC50 index and introduce two new parameters (ICr0 and ICrmed) to compare treatment efficacy under different culture conditions or cell lines. <b>Conclusions</b>: In summary, this study presents a new method to analyze cell viability assays and introduces two more precise parameters, improving the comparison and evaluation of efficacy under different conditions.

PharmaceuticsVol. 17(2)
Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (ES), Asociación Española Contra el Cáncer (ES), Instituto de Investigación en Recursos Cinegéticos (ES), University of Castilla-La Mancha (ES), Universidad Politécnica de Madrid (ES)
Comunidad de Madrid, Ministerio de Ciencia, Innovación y Universidades, Fundación Científica Asociación Española Contra el Cáncer, Universidad Politécnica de Madrid, Ministerio de Ciencia e Innovación, Consejería de Sanidad, Comunidad de Madrid
Good health and well-being
Openalex Percentile: Top 0%
Statistical Methods in Clinical Trials
63.12
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.